Safety and efficacy of low dose sofosbuvir and ribavirin combined with daclatasvir in patients with decompensated HCV cirrhotic patients

Trial Profile

Safety and efficacy of low dose sofosbuvir and ribavirin combined with daclatasvir in patients with decompensated HCV cirrhotic patients

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Dec 2016 New trial record
    • 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top